

DAFTAR PUSTAKA

1. Anugrah J. Hubungan Diabetes Melitus dan Retinopati di RSUD dr. RSUD Soedarso Pontianak Periode Januari - Desember 2010. 2013.
2. Williams R, Colagiuri S, Amutairi R, Montoya ablo A, Basit A, Beran D. IDF Diabetes Atlas. 9th ed. Karuranga S, Malanda B, Saeedi P, Salpea P, editor. International Diabetes Federation. Internation Diabetes Federation; 2019.
3. World Health Organization. Classification of Diabetes Mellitus 2019. Vol. 309, World Health Organization. 2019.
4. Primadi O, Budijanto D, Sibuea F, Widiyanti W, Indrayani YA, Ismandari F. Profil Kesehatan Indonesia 2018. Kurniawan R, Yudianto, Hardhana B, Siswanti T, editor. Jakarta: Kementerian Kesehatan Republik Indonesia; 2019.
5. Kemenkes RI. Laporan Hasil Riset Kesehatan Dasar Indonesia Tahun 2018. Riset Kesehatan Dasar 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan 2019; 2018.
6. Dinas Kesehatan Kota Padang. Profil kesehatan Kota Padang Tahun 2018. Laporan Tahunan. Padang; 2019.
7. Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M. Complications of Diabetes 2017. J Diabetes Res. 2018;2018:4.
8. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. 2008;26(2):77-82.
9. Altomare F, Kherani A, Lovshin J. Retinopathy. Can J Diabetes. 2018;42:255-82.
10. Elvira, Suryawijaya EE. Retinopati Diabetes. Cermin Dunia Kedokt. 2019;46(3):220-4.
11. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2(1):1-25.
12. Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260-77.
13. Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al.

- Global Estimates on the Number of people Blind or Visually impaired by diabetic retinopathy: A meta-analysis from 1990 to 2010. *Diabetes Care*. 2016;39(9):1643–9.
14. Jonas JB, Sabanayagam C. Epidemiology and Risk Factors for Diabetic Retinopathy. 2019;27:20–37.
 15. Barsegian A, Kotlyar B, Lee J, Salifu MO, Mcfarlane SI. Diabetic Retinopathy: Focus on Minority Populations. 2017;3(1):34–45.
 16. Kartasasmita AS. Retinopati Diabetik: Pergeseran Paradigma Kebutaan pada Era Milenial [Internet]. Ditjen Yankes. 2018 [dikutip 22 Januari 2020]. Tersedia pada: <http://www.yankes.kemkes.go.id/read-retinopati-diabetik-pergeseran-paradigma-kebutaan-pada-era-milenial-5984.html>
 17. Dewi PN, Fadrian, Vitresia H. Profil Tingkat Keparahan Retinopati Diabetik Dengan Atau Tanpa Hipertensi di RSUP Dr. M. Djamil Padang. 2016;8(2):204–10.
 18. Mulyati M, Amin R, Santoso B. Kemajuan Visus Penderita Retinopati Diabetik yang Diterapi dengan Laser Fotokoagulasi dan atau Injeksi Intravitreal di Rumah Sakit Mohammad Hoesin Palembang. *Maj Kedokt Sriwij*. 2015;47(2):115–22.
 19. International Council of Ophthalmology. Updated 2017 ICO Guidelines for Diabetic Eye Care. *ICO Guidel Diabet Eye Care*. 2017;1–33.
 20. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Diabetic Retinopathy Preferred Practice Pattern. *Ophthalmology*. 2020;127(1):66–145.
 21. F D, Martin, Maguire MG. Treatment Choice for Diabetic Macular Edema. *N Engl J Med*. 2015;372(13):1260–1.
 22. Ateeq A, Tahir MA. Intravitreal injection of Bevacizumab in diabetic macular edema. 2014;30(6):1383–7.
 23. Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. *Am Acad Ophthalmol*. 2018;125(10):1608–22.

24. Arevalo JF. Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy. 2013;2(1):3–7.
25. Utari NML. Karakteristik dan Perbaikan Tajam Penglihatan Pada Pasien Penyakit Vaskular Retina yang Mendapat Injeksi Bevacizumab Intravitreal di RSUP Sanglah Denpasar. 2016.
26. Yanoff M, Jay S. Ophthalmology. 4th ed. 2014.
27. Cantor LB, Rapuano CJ, Cioffi GA. Retina and Vitreous. In: Basic and Clinical Science Course. San Fransisco: American Academy of Ophthalmology; 2014. p. 89–111.
28. World Health Organization. Blindness and Vision Impairment Prevention : Priority Eye Diseases [Internet]. World Health Organization. [dikutip 23 Januari 2020]. Tersedia pada: <http://www.who.int/blindness/causes/priority/en/index5.html>
29. Jogi R, Jaypee. Basic Ophthalmology. 4th ed. Ahmedabad, Bengaluru, Chennai, Hyderabad, Kochi, editor. New Delhi: Jaypee Brothers Medical Publishers; 2009.
30. Ahmed RA, Khalil SN, Al- Qahtani MAA. Diabetic Retinopathy and The Associated Risk Factors in Diabetes Type 2 Patients in Abha, Saudi Arabia. J Fam Community Med. 2016;23(1):18.
31. Lima VC, Cavaliere GC, Lima MC, Nazario NO, Lima GC. Risk Factors for Diabetic Retinopathy : A Case – Control Study. Int J Retin Vit. 2016;2(21):1–7.
32. Fong DS, Aiello L, Thomas. Retinopathy in Diabetes. 2004;27.
33. Wang SY, Andrews CA, Herman WH, Gardner TW, Stein JD. Incidence and Risk Factors for Developing Diabetic Retinopathy among Youths with Type 1 or Type 2 Diabetes throughout the United States. A. 2017;124(4):424–30.
34. Atchison E, Barkmeier A. The Role of Systemic Risk Factors in Diabetic Retinopathy. Curr Ophthalmol Rep. 2016;4(2):84–9.
35. Mursi ZA, Hendriati H, Isona L. Hubungan Kolesterol LDL dengan Derajat Retinopati Diabetik di Bagian Mata RSUP Dr. M. Djamil Padang

- Periode Januari-Desember 2015. *J Kesehatan Andalas*. 2018;7(4):498.
36. Morrison JL, Hodgson LAB, Lim LL, Al-Qureshi S. Diabetic retinopathy in pregnancy: a review. *Clin Exp Ophthalmol*. 2016;44(4):321–34.
 37. Ganesan S, Raman R, Kulothungan V, Sharma T. Influence of dietary-fibre intake on diabetes and diabetic retinopathy: Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetic Study (report 26). *Clin Exp Ophthalmol*. 2012;40(3):288–94.
 38. Yan X, Han X, Wu C, Keel S, Shang X, Zhang L, et al. Does daily dietary intake affect diabetic retinopathy progression? 10-year results from the 45 and Up Study. *Br J Ophthalmol*. 2019;(January 2004):1–7.
 39. Mishra B, Swaroop A, Kandpal RP. Genetic Components in Diabetic Retinopathy. *Indian J Ophthalmol*. 2016;64(1):55–61.
 40. Safi SZ, Qvist R, Kumar S, Batumalaie K, Shah I, Ismail B. Molecular Mechanisms of Diabetic Retinopathy , General Preventive Strategies , and Novel Therapeutic Targets. 2014;2014(Table 1):18.
 41. Adrian D. Pengaruh Anti-VEGF pada Diabetic Retinopathy. 2017;44(11):809–13.
 42. IU S, Jr FH, WE S. Retinal Vascular Disease : Diabetic Retinopathy. In: American Academy of Ophthalmology Retina / Vitreous Panel. 2nd ed. San Fransisco: American Academy of Ophthalmology; 2009. p. 89–112.
 43. Olver J, LLorraine C. Ophtalmology at a glance. 2nd ed. Olver J, editor. London: Wiley Blackwell Science Ltd; 2014.
 44. Eva PR, Jr. ETC. Vaughan & Asbury's General Ophthalmology. 18th ed. California: McGraw-Hill Lange Medica Book; 2011.
 45. Crick RP, Khaw PT. A Textbook of Clinical Ophthalmology. 3rd ed. Singapore: World Scientific Publishing Co. Pte. Ltd; 2003.
 46. American Academy of Ophthalmology and Staff. Retina and Vitreous. In: American Academy of Ophthalmology. 2011-2012b ed. United State of America; p. 109–32.
 47. Zimmet SK and P. Diabetes eye health. International Diabetes Federation; 2013.
 48. Gupta V, Gupta A, Dogra MR, Singh R. Diabetic Retinopathy Atlas and

- Text. In: 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2009. p. 23–50.
49. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet*. 2010;376(9735):124–36.
 50. Sehu KW, Lee WR. Ophthalmic Pathology. In: Banks M, Pock V, editor. United Kingdom: Blackwell Publishing Ltd; 2005. p. 191–203.
 51. Kraushar MF, Morse PH. Retina and vitreous. In: Risk Prevention in Ophthalmology. 2014. p. 225–35.
 52. Wright AD, Dodson PM. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. *Eye*. 2011;25(7):843–9.
 53. Wubben TJ, Johnson MW, Sohn EH, Peairs JJ, Kay CN, Kim SJ, et al. Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions. *Am J Ophthalmol*. 2019;204:13–8.
 54. Gerstenblith AT, Rabinowitz MP, Barahimi BI, Fecarotta CM, Friedberg MA, Rapuano CJ. *The Wills Eye Manual*. 6th ed. Gerstenblith AT, Rabinowitz MP, Barahimi BI, Fecarotta CM, Friedberg MA, Rapuano CJ, editor. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Business; 2012.
 55. Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside. *Ophthalmology*. 2016;123(10):78–88.
 56. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic Retinopathy and VEGF. *Open Ophthalmol J*. 2013;7(1):4–10.
 57. Jeat AW. Evaluation of Vascular Endothelial Growth Factor Level in Tear and Serum Among Diabetic Patients. *Sains Malaysia*; 2018.
 58. Abcouwer SF. Angiogenic Factors and Cytokines in Diabetic Retinopathy. *J Clin Cell Immunol*. 2011;1(11):1–12.
 59. Djatikusumo A, Adriono GA, Yudantha AR, Marbungaran M, Victor AA. Intravitreal Bevacizumab in Diabetic Macular Edema at Dr . Cipto Mangunkusumo Hospital Jakarta in 2017. 2019;2(2):62–7.
 60. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial

growth factor therapy for diabetic macular edema. *Ther Adv Endocrinol Metab.* 2013;4(6):151–69.

61. Afaq A, Shahid E, Hasan KS ul. Effectiveness of Intravitreal Bevacizumab in Various Ocular Diseases. 2013;29(2):73–9.
62. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. *Eye.* 2013;27(7):787–94.
63. Tsai JC, Denniston AKO, Murray PI, Huang JJ, Aldad TS. *Oxford American Handbook of Ophthalmology.* Tsai JC, Denniston AKO, Murray PI, Huang JJ, Aldad TS, editor. New York: Oxford University Press; 2011.
64. Shikari H, Silva PS, Sun JK. Complications of intravitreal injections in patients with diabetes. *Semin Ophthalmol.* 2014;29(5–6):276–89.
65. Federico Tridico RN. Complications of Intravitreal Anti-VEGF Drugs: A Report on Our Personal Experience. *J Clin Exp Ophthalmol.* 2015;06(04):3–4.
66. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. Complications in patients after intravitreal injection of bevacizumab. *Acta Ophthalmol.* 2008;86(4):372–6.
67. World Health Organization. *World report on vision.* Vol. 214, World Health Organization. 2019.
68. Messina E. Standards of Visual Acuity in Industry. *Br J Ophthalmol.* 2006;21(9):508–9.
69. James B, Chew C, Bron A. *Lecture Notes on Ophthalmology.* 9th ed. Safitri A, editor. Jakarta: Erlangga; 2005.
70. Cheung N, Wong IY, Wong TY. Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical Efficacy and Evolving Applications. *Diabetes Care.* 2014;37(4):900–5.
71. Torabi H. Management of Refractory Diabetic Macular Edema: A Review Article. *Int J Med Rev.* 2018;5(1):27–34.
72. Ayu YS. Perbandingan Tajam Penglihatan Sebelum dan Sesudah Terapi Serial Injeksi Intravitreal Anti-VEGF Pada Penderita Retinopati Diabetik di RSUP Dr. Mohammad Hoesin Palembang. Universitas Sriwijaya; 2019.

73. Yun JS, Lim TS, Cha SA, Ahn YB. Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea. *Diabetes Metab J.* 2016;40(1):482–93.
74. Cornel S, Adriana ID, Mihaela TC, Speranta S, Algerino DS, Mehdi B, et al. Anti - Vascular Endothelial Growth Factor Indications in Ocular Disease. *Rom J Ophthalmol.* 2015;59(4):235–42.
75. Yonekawa Y, Modi YS, Kim LA, Skondra D, Kim JE, Wykoff CC. American Society of Retina Specialists Clinical Practice Guidelines: Management of Nonproliferative and Proliferative Diabetic Retinopathy Without Diabetic Macular Edema. *J Vitreoretin Dis.* 2020;4(2):125–35.
76. Mansour AM, Ashraf M, El Jawhari KM, Farah M, Souka A, Sarvaiya C, et al. Intravitreal Ziv-Aflibercept in Diabetic Vitreous Hemorrhage. *Int J Retin Vitre.* 2020;6(2):19–22.
77. Mehany SA, Mourad KM, Shawkat AM, Sayed MF. Early Avastin management in acute retinal vein occlusion. *Saudi J Ophthalmol.* 2010;24(3):87–94.
78. Jaisle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, et al. Predictive Factors for Functional Improvement After Intravitreal Bevacizumab Therapy for Macular Edema Due to Branch Retinal Vein Occlusion. *Graefe's Arch Clin Exp Ophthalmol.* 2011;249(2):183–92.
79. Koss MJ, Naser H, Sener A, Ackermann H, Al-Sarireh F, Singh P, et al. Combination Therapy in Diabetic Macular Oedema and Retinal Vein Occlusion - Past and Present. *Acta Ophthalmol.* 2010;1–10.
80. Elvira, Suryawijaya EE. Retinopati Diabetes. 2019;46(3):220–4.
81. Zhao Y, Singh RP. The Role of Anti-Vascular Endothelial Growth Factor (anti-VEGF) In The Management of Proliferative Diabetic Retinopathy. *Drugs Context.* 2018;7:1–10.
82. Sinawat S, Rattanapakorn T, Sanguansak T, Yospaiboon Y. Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation. *Eye.* 2013;27(12):1391–6.
83. Stefanini FR os., Badaró E, Falabella P, Koss M, Farah ME i., Maia M.

- Anti-VEGF for the Management of Diabetic Macular Edema. *J Immunol Res.* 2014;2014:1–8.
84. Wong WM, Chee C, Bhargava M, Chai C, Lin H, Zhao P, et al. Systemic Factors Associated with Treatment Response in Diabetic Macular Edema. *J Ophthalmol.* 2020;2020:1–6.
85. Pratiwi LA. Hubungan Pengetahuan Pasien Mengenai Penyakit Retinopati Diabetik dan Informasi Oleh Tenaga Kesehatan Serta Biaya Kesehatan Pada Pasien Diabetes Melitus Terhadap Kepatuhan Pemeriksaan Mata di Puskesmas Kedaton. Universitas Lampung. 2018.

